Objective: To review atypical/positive urine cytology specimens from patients with confirmed prostatic duct adenocarcinoma (PDA), describe the cytomorphologic features and discuss the differential diagnosis. Study Design: A retrospective review of the cytopathology archives of The Johns Hopkins Hospital revealed 14 cases of abnormal urinary cytology in patients with histologically confirmed PDAs. Cytologic material was reviewed; cytomorphologic characteristics were analyzed and correlated with histopathologic features wherever possible. Results: There were 7 patients ranging in age from 52 to 80 years (mean age: 68 years). The clinical presentation included; hematuria, bladder obstruction and perineal mass. The cytomorphologic characteristics were: large crowded sheets and three-dimensional fragments (some with papillary architecture) of columnar epithelium with scant amphophilic cytoplasm, basally placed round to oval nuclei with coarse chromatin and absent or inconspicuous nucleoli. Histologic findings showed papillary and cribriform architecture of columnar cells with crowding, nuclear stratification and overlapping with or without nucleoli. Conclusion: PDAs usually present at an advanced clinical stage and may exfoliate owing to their location in the central prostatic urethra. Differentiating PDA from acinar prostatic adenocarcinoma, urothelial carcinoma and metastatic adenocarcinoma is important due to the differences in patient management. Since prostate-specific antigen values are variable, urine cytology may provide a valuable tool for the early detection of these aggressive lesions.

Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.